DRUG OF THE DAY
metoprolol succinate extended-release
Beta1-selective adrenergic blocker
Before opening the card, recall one use, one safety check and one counseling point.
Reveal the drug learning card
Names and formulations
- Toprol-XL: extended-release; distinct from metoprolol tartrate immediate-release
Succinate ER and tartrate IR differ in release pattern, usual dosing frequency, and labeled uses; verify the salt and dosage form during transitions.
Common use
Hypertension, angina, and stable symptomatic heart failure of ischemic, hypertensive, or cardiomyopathic origin.
Mechanism of action
Blocks cardiac beta1 receptors, reducing heart rate, contractility, and renin release; beta1 selectivity diminishes at higher concentrations.
Important adverse effects and monitoring
- Monitor heart rate, blood pressure, dizziness, and signs of worsening heart failure during titration.
- Abrupt withdrawal can worsen angina and precipitate myocardial infarction.
- May mask some warning signs of hypoglycemia and can contribute to bronchospasm in susceptible patients.
Patient counseling
- Do not stop suddenly without prescriber guidance.
- Extended-release tablets may be divided if scored, but should not be crushed or chewed.
Interaction to recognize
With: strong CYP2D6 inhibitors such as fluoxetine, paroxetine, quinidine, or propafenone
Why it matters: May increase metoprolol concentrations and beta-blocking effects.
Practical response: Monitor for bradycardia, hypotension, or intolerance and adjust therapy if needed.
Check the original sources
- DailyMed — Toprol-XL (metoprolol succinate ER) prescribing information
Sections: 1 Indications and Usage; 2 Dosage and Administration; 5 Warnings and Precautions; 7 Drug Interactions; 12.1 Mechanism of Action; 17 Patient Counseling Information. Source checked 2026-09-13.
Selected learning points; verify current labeling for the complete prescribing information.